COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution
Hardman & Co Research provides analysis on Shield Therapeutics (STX) focusing on successful execution. Shield progressing well with sales traction and cost control, aiming for cashflow-break even in 2H'25 -
COMMUNIQUÉ DE PRESSE
Santé Canada approuve (Pr)CABTREO(MC) (phosphate de clindamycine, adapalène et peroxyde de benzoyle), un traitement topique à triple combinaison pour l'acné vulgaire chez les patients âgés de 12 ans et plus
Bausch Health Canada Inc. annonce l'approbation par Santé Canada de PrCABTREO, traitement topique à triple combinaison pour l'acné vulgaire. Disponible Q4 2024 -
COMMUNIQUÉ DE PRESSE
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older
Bausch Health, Canada, part of Bausch Health Companies, receives Health Canada approval for new acne treatment CABTREO, a triple-combination topical gel. Dermatology breakthrough for Canadians -
-
-
-
COMMUNIQUÉ DE PRESSE
Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota
Zomedica Corp. completes renovation of manufacturing and distribution facilities in Minnesota, enhancing manufacturing capacity and shipping efficiencies for TRUFORMA cartridges -
-
